Business as usual for CCL Oncology / Virology services with new test announced

CCL has worked rapidly to introduce the new Covid-19 testing service recently, but during the upheaval of the last few months our existing Virology and Oncology testing has continued as normal. 

Latest news 

To expand our Urology offering we are proud to announce our latest partnership with Nucleix, Israel and their unique Bladder Epicheck test which we hope will help reduce the increasing incidence of bladder cancer in the UK.

Bladder cancer - did you know?

·    It is the tenth most common cancer in the UK - 3% of all new cases

·    Nearly 100,000 people are living with it in the UK

·    Over 10,000 people in the UK are diagnosed each year (28 every day)

·    50% of those diagnosed will die of the disease 

·    Diagnosis is often too late - around 25% of all cases are diagnosed at a late stage, particularly in women

·    It has the highest recurrence rate of any known cancer - up to 80%

·    It is the only top ten cancer where rates of prognosis are getting worse

·    It is one of the most expensive cancers for the NHS to treat costing £65million annually

·    Bladder cancer received 0.6% of dedicated research funding in 2013-2014

Source: Action Bladder Cancer UK

Finding out more

If you are a Health Care Professional wanting to know more about this test please contact CCL at info@camclinlabs.co.uk / 01223 395450. If you are a patient wanting to know more about this test please speak with your healthcare provider. 

---

For the latest follow our social media feeds:

·      Twitter @camclinlabs 

·       LinkedIn @Cambridge Clinical Laboratories